Search Results - "TAKEZAWA, Ken"

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor-Induced Apoptosis in EML4-ALK-Positive Lung Cancer by TAKEZAWA, Ken, OKAMOTO, Isamu, NISHIO, Kazuto, JÄNNE, Pasi A, NAKAGAWA, Kazuhiko

“…EML4-ALK (echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell…”
Get full text

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations by Tanizaki, Junko, Okamoto, Isamu, Okamoto, Kunio, Takezawa, Ken, Kuwata, Kiyoko, Yamaguchi, Haruka, Nakagawa, Kazuhiko

“…Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in patients with solid tumors, but the precise mechanism of the antitumor…”
Get more information

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK―Positive Non―Small Cell Lung Cancer by TANIZAKI, Junko, OKAMOTO, Isamu, HATASHITA, Erina, NISHIO, Kazuto, NAKAGAWA, Kazuhiko, OKABE, Takafumi, SAKAI, Kazuko, TANAKA, Kaoru, HAYASHI, Hidetoshi, KANEDA, Hiroyasu, TAKEZAWA, Ken, KUWATA, Kiyoko, YAMAGUCHI, Haruka

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) such as crizotinib show marked efficacy in patients with non-small cell lung cancer positive…”
Get full text

Sorafenib Inhibits Non―Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells by TAKEZAWA, Ken, OKAMOTO, Isamu, YONESAKA, Kimio, HATASHITA, Erina, YAMADA, Yuki, FUKUOKA, Masahiro, NAKAGAWA, Kazuhiko

“…Sorafenib is a multikinase inhibitor whose targets include B-RAF and C-RAF, both of which function in the extracellular signal-regulated kinase (ERK) signaling…”
Get full text

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations by Okamoto, Kunio, Okamoto, Isamu, Okamoto, Wataru, Tanaka, Kaoru, Takezawa, Ken, Kuwata, Kiyoko, Yamaguchi, Haruka, Nishio, Kazuto, Nakagawa, Kazuhiko

“…The molecular mechanism by which epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) induce apoptosis in non-small cell-lung cancer (NSCLC)…”
Get full text

Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition by Okamoto, Wataru, Okamoto, Isamu, Yoshida, Takeshi, Okamoto, Kunio, Takezawa, Ken, Hatashita, Erina, Yamada, Yuki, Kuwata, Kiyoko, Arao, Tokuzo, Yanagihara, Kazuyoshi, Fukuoka, Masahiro, Nishio, Kazuto, Nakagawa, Kazuhiko

“…Therapeutic strategies that target c-Src hold promise for a wide variety of cancers. We have now investigated both the effects of dasatinib, which inhibits the…”
Get full text

Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis by Takezawa, Ken, Okamoto, Isamu, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Cancer chemotherapy is not well established for patients on hemodialysis (HD). A 77-year-old man on HD presented with small cell lung cancer. He was treated…”
Get more information

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer by Sakai, Kazuko, Okamoto, Isamu, Takezawa, Ken, Hirashima, Tomonori, Kaneda, Hiroyasu, Takeda, Masayuki, Matsumoto, Kazuko, Kimura, Hideharu, Fujita, Yoshihiko, Nakagawa, Kazuhiko, Arao, Tokuzo, Nishio, Kazuto

“…The presence of the transforming fusion gene echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small-cell lung…”
Get more information

Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients by Okamoto, Kunio, Okamoto, Isamu, Takezawa, Ken, Tachibana, Izumi, Fukuoka, Masahiro, Nishimura, Yasumasa, Nakagawa, Kazuhiko

“…Objective The optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established. Methods The records of…”
Get full text

Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor by Takezawa, Ken, Okamoto, Isamu, Tanizaki, Junko, Kuwata, Kiyoko, Yamaguchi, Haruka, Fukuoka, Masahiro, Nishio, Kazuto, Nakagawa, Kazuhiko

“…Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth factor receptor (EGFR) are initially responsive to…”
Get full text

Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification by Tanizaki, Junko, Okamoto, Isamu, Takezawa, Ken, Tsukioka, Sayaka, Uchida, Junji, Kiniwa, Mamoru, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Amplification of human epidermal growth factor receptor 2 (HER2) has been detected in 20% to 30% of gastric cancers and is associated with a poor outcome…”
Get full text

Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas by Pirazzoli, Valentina, Takezawa, Ken, de Stanchina, Elisa, Pao, William, Politi, Katerina

“…The epidermal growth factor receptor (EGFR) T790M mutation confers acquired resistance to tyrosine kinase inhibitors (TKIs) in approximately 50% of…”
Get full text

Abstract 4446: Activation of HER Family signaling as a mechanism of acquired resistance to ALK Inhibitors in EML4-ALK-positive Non-Small Cell Lung Cancer by Tanizaki, Junko, Okamoto, Isamu, Okabe, Takafumi, Sakai, Kazuko, Tanaka, Kaoru, Hayashi, Hidetoshi, Kaneda, Hiroyasu, Takezawa, Ken, Nishio, Kazuto, Nakagawa, Kazuhiko

“…Purpose: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) such as crizotinib show marked efficacy in patients with non-small cell lung cancer…”
Get full text

Abstract 3858: Synergistic antitumor effects of combination therapy with S-1 and HER2 targeting agents in gastric cancer with HER2 amplification by Tanizaki, Junko, Okamoto, Isamu, Takezawa, Ken, Tsukioka, Sayaka, Uchida, Junji, Kiniwa, Mamoru, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…HER2 amplification is observed in 20-30% of gastric cancer and it has been correlated to poor outcomes and more aggressive disease. Combination therapies with…”
Get full text

Abstract 2505: Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells by Takezawa, Ken, Okamoto, Isamu, Yonesaka, Kimio, Yamada, Yuki, Hatashita, Erina, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Sorafenib is a multikinase inhibitor whose targets include B-RAF and C-RAF, both of which function in the extracellular signal-regulated kinase (ERK) signaling…”
Get full text

Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer by Takezawa, Ken, Melnick, Mary Ann, Riely, Greg, Kris, Mark, Miller, Vincent, Ladanyi, Marc, Politi, Katerina, Pao, William, Pirazzoli, Valentina, Song, Xiaoling, Arcila, Maria, De Stanchina, Elisa, Ohashi, Kadoaki, Janjigian, Yelena, Spitzler, Paula, Nebhan, Caroline

“…EGFR mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib. The combination of an…”
Get full text

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer by Hasegawa, Yoshikazu, Okamoto, Isamu, Takezawa, Ken, Miyazaki, Masaaki, Tsurutani, Junji, Yonesaka, Kimio, Morinaga, Ryotaroh, Tsuya, Asuka, Terashima, Masaaki, Kudoh, Toshihiro, Azuma, Koichi, Kurata, Takayasu, Nishikawa, Tatsuyuki, Fukuoka, Masahiro, Nishimura, Yasumasa, Nakagawa, Kazuhiko

“…Summary Background A phase I study was performed to evaluate dose-limiting toxicity and the recommended dose for the oral fluoropyrimidine S-1 administered…”
Get full text

Large cell neuroendocrine carcinoma of the mediastinum with alpha-fetoprotein production by Takezawa, Ken, Okamoto, Isamu, Fukuoka, Junya, Tanaka, Kaoru, Kaneda, Hiroyasu, Uejima, Hisao, Yoon, Hyung-Eun, Imakita, Masami, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Large cell neuroendocrine carcinoma (LCNEC) is a relatively new category of pulmonary neuroendocrine tumor. Although it was first detected in the lung, LCNEC…”
Get more information

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation by Takezawa, Ken, Pirazzoli, Valentina, Arcila, Maria E, Nebhan, Caroline A, Song, Xiaoling, de Stanchina, Elisa, Ohashi, Kadoaki, Janjigian, Yelena Y, Spitzler, Paula J, Melnick, Mary Ann, Riely, Greg J, Kris, Mark G, Miller, Vincent A, Ladanyi, Marc, Politi, Katerina, Pao, William

“…EGF receptor (EGFR)-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKI). The combination of EGFR-TKI…”
Get more information